The CDC states SHINGRIX is1:
|Recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years|
|Recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL)|
|Preferred over ZVL for the prevention of herpes zoster and related complications|
Please see Important Considerations below.
2018 CDC Recommendations: Important Considerations Related to Alternate Dosing, Concomitant Use, Patients Previously Vaccinated With ZVL, and Persons With a Prior History of Herpes Zoster
This article contains dosing schedule information that is inconsistent with the label. According to the Prescribing Information for SHINGRIX, 2 doses (0.5 mL each) should be administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.2
SHINGRIX was administered concomitantly with FLUARIX QUADRIVALENT (Influenza Vaccine) in an open-label clinical study of subjects 50 years and older (N=828). There was no evidence of interference in the immune response to any of the antigens contained in SHINGRIX or the coadministered vaccine. Evaluation of coadministration of SHINGRIX with other vaccines is ongoing.2
Patients Previously Vaccinated With ZVL
Persons With a Prior History of Herpes Zoster
The pivotal clinical trials for SHINGRIX excluded patients with a prior history of herpes zoster. Studies of the safety and immunogenicity of SHINGRIX in patients with a prior history of herpes zoster are ongoing.
There are no head-to-head clinical trials comparing the efficacy and safety of SHINGRIX to ZVL
*ACIP recommendations adopted by the CDC.
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention.
References: 1. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 2. Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343-1351.
All trademarks are the property of their respective owners.
1004182R0 April 2018